Aneuploidy fraction but not DNA index is important for the prognosis of patients with stage I and II breast cancer--10-year results - PubMed (original) (raw)
Aneuploidy fraction but not DNA index is important for the prognosis of patients with stage I and II breast cancer--10-year results
M F Gnant et al. Ann Oncol. 1993 Sep.
Free article
Abstract
Background: Individual assessment of the prognosis of patients with breast cancer is crucial for the selection of risk-adapted adjuvant therapy and in follow-up. Parameters from DNA flow-cytometry have been shown to provide significant prognostic information, but published results are in conflict and there are only a few investigations with long-term follow-up. The aim of this study is to clarify the impact of tumor DNA data on the clinical course of stage I and stage II breast cancer patients.
Patients and methods: Several flow-cytometry DNA analyses were performed on tumor samples derived from 191 breast cancer patients entered in a controlled clinical trial after a median follow-up of more than 10 years. In addition to DNA index (DNI) and the percentage of cells in S phase (SPF), an index, designated aneuploidy fraction (AF), was determined. It ascertains the percentage of aneuploid cells out of all cells in the DNA flow-cytometry histogram, and its reproducibility has been tested by measurements of AF in two different samples of the same tumor. Univariate analyses and, in the 122 patients for whom complete information was available, a Cox model, were performed to investigate the individual prognostic impact of flow-cytometry parameters compared with established clinical factors.
Results: AF proved to be a very valuable prognostic indicator both in univariate and multivariate analyses, whereas DNI and SPF failed to provide independent prognostic information. The combination of AF and lymph node status clearly identifies different prognostic subgroups in operable breast cancer.
Conclusions: Routine evaluation of patients with breast cancer should include tumor DNA flow-cytometry. Aneuploidy fraction is a valuable tool in assessing an individual patient's prognosis and thus can help in the choice of the appropriate adjuvant treatment strategy. Whether it, rather than DNI and SPF should be used, as we found, needs to be validated in a larger prospective investigation.
Similar articles
- DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer: 10 year results of a randomised study.
Gnant MF, Blijham G, Reiner A, Reiner G, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R. Gnant MF, et al. Eur J Cancer. 1992;28(2-3):711-6. doi: 10.1016/s0959-8049(05)80132-7. Eur J Cancer. 1992. PMID: 1591097 Clinical Trial. - Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer.
Kallioniemi OP, Blanco G, Alavaikko M, Hietanen T, Mattila J, Lauslahti K, Lehtinen M, Koivula T. Kallioniemi OP, et al. Cancer. 1988 Nov 15;62(10):2183-90. doi: 10.1002/1097-0142(19881115)62:10<2183::aid-cncr2820621019>3.0.co;2-b. Cancer. 1988. PMID: 3179930 - Prognostic significance of DNA image cytometry in Libyan breast cancer.
Ermiah E, Abdalla F, Buhmeida A, Alshrad M, Salem N, Pyrhönen S, Collan Y. Ermiah E, et al. Oncology. 2012;83(3):165-76. doi: 10.1159/000339788. Epub 2012 Aug 15. Oncology. 2012. PMID: 22906963 - Prognostic significance of morphological parameters and flow cytometric DNA analysis in carcinoma of the breast.
Visscher DW, Zarbo RJ, Greenawald KA, Crissman JD. Visscher DW, et al. Pathol Annu. 1990;25 Pt 1:171-210. Pathol Annu. 1990. PMID: 2153277 Review. - [Breast cancer and flow cytometry: comparative study of DNA ploidy pattern with clinicopathological parameters].
Araya JC, Roa I, Wistuba I, Villaseca MA, Contreras E, Olcese A, Danton A, Watanabe H. Araya JC, et al. Rev Med Chil. 1994 Jun;122(6):643-52. Rev Med Chil. 1994. PMID: 7732208 Review. Spanish.
Cited by
- Human Papillomavirus-Induced Chromosomal Instability and Aneuploidy in Squamous Cell Cancers.
Mallick S, Choi Y, Taylor AM, Cosper PF. Mallick S, et al. Viruses. 2024 Mar 25;16(4):501. doi: 10.3390/v16040501. Viruses. 2024. PMID: 38675844 Free PMC article. Review. - Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators.
Levesque MA, Clark GM, Yu H, Diamandis EP. Levesque MA, et al. Br J Cancer. 1995 Sep;72(3):720-7. doi: 10.1038/bjc.1995.400. Br J Cancer. 1995. PMID: 7545416 Free PMC article. - c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates.
Mezzelani A, Alasio L, Bartoli C, Bonora MG, Pierotti MA, Rilke F, Pilotti S. Mezzelani A, et al. Br J Cancer. 1999 May;80(3-4):519-25. doi: 10.1038/sj.bjc.6690387. Br J Cancer. 1999. PMID: 10408862 Free PMC article. - Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells.
Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Knudsen ES, Sotgia F, Lisanti MP. Martinez-Outschoorn UE, et al. Cell Cycle. 2010 Aug 15;9(16):3256-76. doi: 10.4161/cc.9.16.12553. Epub 2010 Aug 28. Cell Cycle. 2010. PMID: 20814239 Free PMC article. - Interphase cytogenetics reveals a high incidence of aneuploidy and intra-tumour heterogeneity in breast cancer.
Fiegl M, Tueni C, Schenk T, Jakesz R, Gnant M, Reiner A, Rudas M, Pirc-Danoewinata H, Marosi C, Huber H, et al. Fiegl M, et al. Br J Cancer. 1995 Jul;72(1):51-5. doi: 10.1038/bjc.1995.276. Br J Cancer. 1995. PMID: 7599066 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical